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Abstract
Background: Veno-occlusive disease, Graft-versus-Host disease, invasive or localized bacterial, viral and fungal
infections are known as adverse events after hematopoietic stem cell transplantation representing the major cause
for morbidity and mortality. Detection and differentiation of these adverse events are based on clinical symptoms
and routine measurements of laboratory parameters.
Methods: To identify the role of cytokines as a possible complication-marker for adverse events, 61 consecutive
pediatric patients with a median age of 7.0 years who underwent hematopoietic stem cell transplantation were
enrolled in this single-center retrospective study. Interleukin-1 beta (IL-1β), soluble interleukin-2 receptor (sIL-2R),
interleukin-6 (IL-6), interleukin-8 (IL-8), interleukin-10 (IL-10) and tumor necrosis factor-α serum (TNF-α) levels were
regularly assessed after transplantation and during transplantation related adverse events.
Results: Veno-occlusive disease was accompanied by a significant increase in levels of IL-6, IL-8 and TNF-α.Graft-
versus-Host disease was associated with a significant increase of IL-10, sIL-2R, IL-6 and TNF-α, depending on the
respective stage or grade. Cytokine IL-6 enabled a significant differentiation between sepsis and fungemia, sepsis
and viremia, and sepsis and bacteremia. Moreover, cytokine IL-8 enabled a significant differentiation between sepsis
and viremia, sepsis and bacteremia, and bacteremia and viremia whereas IL-10 made a distinction between sepsis
and viremia possible.
Conclusion: The data demonstrate that proinflammatory cytokines might be putative indicators for early detection
and differentiation of post-transplant adverse events and may allow prompt and adequate clinical intervention.
Prospective clinical trials are needed to evaluate these findings.
Background
Post-transplant adverse events such as sepsis, bacterial,
viral or fungal infections, acute Graft-versus-Host disease
(GvHD) and veno-occlusive disease (VOD) are major
causes of morbidity and mortality after hematopoietic
stem cell transplantation (HSCT) [1–6]. Numerous re-
ports have demonstrated that certain cytokines are
released during the conditioning and post-transplant pe-
riods [7–12]. Interleukin 8 (IL-8) is known to increase
drastically one to four days after the diagnosis of a severe
VOD while soluble interleukin-2 receptor sIL-2R (sIL-2R)
seems to increase significantly during VOD [13, 14]. This
increase was reported to be significantly higher than in
patients with GvHD grade II or III during the post-
transplant period. Patients with VOD or GvHD grade II or
III experience an increase of the inflammatory cytokines
interleukin 6 (IL-6) and tumor necrosis factor-α (TNF-α).
Patients with severe acute GvHD grade III or IV after
HSCT show a significant increase in interleukin 10 (IL-10)
levels between the aplastic phase and the leukocyte recov-
ery phase after transplantation in comparison to patients
that do not develop GvHD [15]. In the first 15 weeks of
the post-transplantation period, serum levels of sIL-2R
and IL-10 are significantly higher in transplanted patients
that develop GvHD than in patients without GvHD [16].
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Patients with higher levels of TNF-α and IL-10 at two
weeks after HSCT develop moderate-to-severe GvHD in
the post-transplant period in comparison to patients with
relatively lower TNF-α and IL-10 levels which can be
correlated with a lower GvHD grade [17]. An increase in
IL-6 and IL-10 levels can be observed during acute GvHD
grade II and more in the early post-transplant period,
while the levels of TNF-α and IL-8 remain unchanged
[10]. Other studies have reported an increase in TNF-α
level at the onset of GvHD [18–20].
IL-6 plays a decisive role in the trans-signaling patho-
genesis of sepsis [21]. It could be shown that IL-6 and
IL-8 are reliable indicators that enable the differenti-
ation of pediatric oncology patients with short duration
of fever episodes from patients with severe infection or
even blood culture positive sepsis [22]. IL-8 was shown
to be a highly sensitive predictor for pediatric oncology
patients at low risk for bacteremia [23] while IL-10 was
shown to correlate with bacteremia and sepsis [24]. In
14 HSCT recipients with a human herpes virus 6
(HHV-6) reactivation after HSCT, IL-6 and TNF-α
levels were significantly higher than in recipients with-
out an HHV-6 viremia [9]. Further, it could be shown
that renal transplant patients that suffer from post-
transplant cytomegalovirus (CMV) viremia develop in-
creased sIL-2R, IL-6, and IL-10 cytokine levels [25].
Serum levels of IL-8, IL-6, IL-10 and C-reactive protein
(CRP) could be used as differentiation markers for high
and low risk pediatric oncology patients with neutro-
penia [26] whereas in adult oncology patients, serum
concentrations of CRP, IL-6, IL-8 and sIL-2R were
elevated in the afebrile neutropenic period [27].
Taken together, the presented results display the cru-
cial role of cytokines in these immunologic phenomena
but still, sufficient knowledge about cytokine pattern is
not available yet for early identification and differenti-
ation of the various types of adverse events such as
localized viral infections. It is currently not possible to
identify and distinguish a VOD from an acute liver
GvHD, a bacteremia from a viremia or fungemia, or
diarrhea caused by a localized viral infection in feces
from an intestinal GvHD. In order to provide insight
into these issues the present study addresses the ana-
lysis of interleukin 1β (IL-1β), sIL-2R, IL-6, IL-8, IL-10,
and TNF-α serum levels in regular intervals after allo-
geneic and autologous HSCT in pediatric patients. The
data were analyzed with respect to the patient’s clinical
presentation.
The priority objective of the present study was to
analyze whether early identification of major post-
transplant related adverse events in pediatric patients with
hemato-oncological malignancies and non-malignancies
after allogeneic and autologous HSCT is possible through
the examination of cytokine levels.
Methods
Ethics
This analysis was conducted in accordance with the Dec-
laration of Helsinki and performed under the waiver for
retrospective anonymized studies in accordance with the
Independent Ethics Committee (IEC) of the Eberhard-
Karls-University Tuebingen. Written informed consent
was obtained by the patients or their legal representatives.
Survey design and patient characteristics
This retrospective single-center investigation comprises
a longitudinal analysis of cytokine levels IL-1β, sIL-2R,
IL-6, IL-8, IL-10, and TNF-α of consecutive pediatric
patients before, during and after allogeneic (n = 59) and
autologous (n = 2) HSCT. The analysis was a single
cohort, with baseline samples from each patient, which
was subsequently divided into a group of patients with-
out complications during therapy and patients with one
of several defined complications. The observation period
was defined as the period from the day before start of
the conditioning regimen until the date of discharge
after HSCT. The patient group consisted of 61 pediatric
patients and young adults (36 males, 25 females) with a
median age of 7.0 years (range 0.5 – 26 years) undergo-
ing HSCT for hemato-oncological malignancies and in-
born errors of metabolism. Patients received transplants
from mismatched family donors (MMFD, n = 38),
matched unrelated donors (MUD, n = 16), HLA-identical
siblings (n = 5) or patients who underwent autologous
transplantation (n = 2). All autologous and allogeneic
transplant recipients received standard prophylaxis in-
cluding antimycotics, virostatics and metronidazole. On
day four after HSCT, all allogeneic transplanted patients
received granulocyte colony-stimulating factor (G-CSF)
at a dosage of 5 μg per kg body weight and day (mg/kg
BW/d) until leukocytes stabilized (>1000/μl) and neutro-
phils reached levels of >500/μl. GvHD prophylaxis was
applied depending on the type of transplantation intra-
venously with cyclosporine A (CsA), mycophenolate mo-
fetil, anti-thymocyte globulin (ATG), methotrexate or
muromonab-CD3.
Thirteen of the 61 patients did not suffer from post-
transplant complications such as VOD, GvHD, sepsis,
invasive or localized bacterial, viral or fungal infection.
Patient characteristics are summarized in Table 1.
Criteria for the assessment of post-transplant adverse
events
Diagnosis of VOD was made according to the Seattle or
Baltimore clinical criteria [28–30]. No liver biopsy or ana-
lysis of plasminogen activator inhibitor-1 (PAI-1) level was
performed in patients diagnosed with VOD. Clinical diag-
nosis of acute GvHD followed the criteria of Glucksberg
and colleagues [31]. Sepsis was evaluated according to the
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criteria of the International Sepsis Consensus Conference
on Paediatric Critical Care 2005 [32]. Bacteremia was
diagnosed with at least one positive blood culture. Viremia
was defined as a positive polymerase chain reaction ana-
lysis resulting from blood for CMV, adenovirus (ADV),
HHV-6, Epstein-Barr virus (EBV), varicella zoster virus
(VZV), human herpes simplex virus (HSV) and Parvovirus
B19. A local bacterial and viral infection, i.e., a non-
invasive bacterial, viral or fungal infection in the blood
was defined as a positive microbiological or virological test
of infection in the throat, urine or feces. Proven or prob-
able invasive fungal infections were defined in accordance
with the definitions for invasive fungal diseases presented
by the Invasive Fungal Infections Cooperative Group of
the European Organization for Research and Treatment
of Cancer and the National Institute of Allergy and Infec-
tious Diseases Mycoses Study Group (EORTC/MSG) [33].
Blood sampling and laboratory analyses
In 61 patients, the levels of the cytokines IL-1ß, sIL-2R,
IL-6, IL-8, IL-10 and TNF-α were measured as a part of
the routine blood analyses on the morning before start
of conditioning, twice during the conditioning period
and after HSCT, as well as two times per week up to the
time of clinical discharge. The blood samples were taken
between 6:00 a.m. and 8:00 a.m.
IL-1ß was measured using an enzyme linked im-
munosorbent assay (ELISA, R&D Systems, Wiesbaden,
Germany). The levels of sIL-2R, IL-6, IL-8, IL-10 and
TNF-α were measured by chemoluminescent immunoas-
says (Immulite, Siemens Healthcare, Erlangen, Germany).
The reference values were as followed: <0.5 pg/ml for
IL-1ß, <1000 U/ml for s-IL-2R, <5.0 pg/ml for IL-6, <70 pg/
ml for IL-8, <10 pg/ml for IL-10 and <8 pg/ml for TNF-α.
Statistical analysis
All 61 pediatric and adolescent patients were included in
the statistical analyses. The analyzed cytokine levels were
measured before the start of treatment with the condi-
tioning of all 61 pediatric patients. The time designated
before post-transplant adverse event (=baseline) was
defined as the time of the last cytokine level measure-
ment before occurrence of any transplant-related adverse
event. The time called “post-transplant adverse event”,
referred to the first measurement of cytokine levels at
Table 1 Patient characteristics
Patients without Patients with
post-transplant adverse events
n = 13 n = 48
No. [%] No. [%]
Sex
Male 7 (53.8) 29 (60.4)
Female 6 (46.2) 19 (39.6)
Age group
<6 y 6 (46.2) 15 (31.3)
6–12 y 3 (23.1) 18 (37.5)
13–26 y 4 (30.8) 15 (31.3)
Donor
MUD 3 (23.1) 13 (27.1)
MMFD 7 (53.8) 31 (64.6)
MFD 1 (7.7) 4 (8.3)
Autologous 2 (15.4) 0 (0.0)
Primary diagnosis
ALL 1 (7.7) 11 (22.9)
ALL relapse 0 (0.0) 11 (22.9)
AML 0 (0.0) 3 (6.3)
AML relapse 1 (7.7) 4 (8.3)
CML 1 (7.7) 2 (4.2)
JMML 1 (7.7) 1 (2.1)
MDS 0 (0.0) 4 (8.3)
T-NHL 0 (0.0) 1 (2.1)
Solid tumors 3 (23.1) 3 (6.3)
Aplastic anemia 0 (0.0) 1 (2.1)
Neurometabolic
disease
1 (7.7) 3 (6.3)
Immunologic
disease
2 (15.4) 3 (6.3)
Autoimmune
disease
2 (15.4) 0 (0.0)
Chédiak-Higashi
syndrome
1 (7.7) 0 (0.0)
Kostmann disease 0 (0.0) 1 (2.1)
Neurologic disease 0 (0.0) 0 (0.0)
Radiation
TLI 0 (0.0) 3 (6.3)
TBI 1 (7.7) 7 (14.6)
GvHD prophylaxis
CsA +MTX 3 (23.1) 11 (22.9)
CsA 1 (7.7) 6 (12.5)
Acute GvHD
Grade I 0 (0.0) 11 (22.9)
Grade II 0 (0.0) 9 (18.8)
Table 1 Patient characteristics (Continued)
Grade III 0 (0.0) 3 (6.3)
Grade IV 0 (0.0) 1 (2.1)
Abbreviations: ALL acute lymphoblastic leukemia, AML acute myeloid leukemia,
CML chronic myeloid leukemia, CsA cyclosporine A, GvHD graft-versus-host
disease, JMML juvenile myelomonocytic leukemia, MDS myelodysplastic
syndromes, MFD matched family donor, MMFD mismatched family donor, MTX
methotrexate, MUD matched unrelated donor, TBI total body irradiation, TLI
total lymphoid irradiation, T-NHL T cell non-Hodgkin’s lymphoma, y year(s)
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the beginning of the first clinical symptoms or labora-
tory chemical changes, which were related to observed
post-transplant adverse events. The cytokine data are pre-
sented as median values and range, or means + standard
deviation (SD). Non-parametric statistical tests were ap-
plied because of frequent non-normality of data sets
(tested by the Shapiro-Wilk normality test), or small or
unequal sample sizes. The Wilcoxon matched pairs signed
rank test was applied for statistical comparisons of the
cytokine levels between “before post-transplant adverse
event”, and “post-transplant adverse event“. For the com-
parisons between MUD versus MFD, MUD versus MMFD
and total body irradiation (TBI) versus non-TBI, the
Mann–Whitney test was used for these unpaired data.
The presented values for the group without complications
were taken from 13 of the 61 pediatric patients at the
point in time “before treatment”. P values of p ≤ 0.05 (*),
p ≤ 0.01 (**) and p ≤ 0.001 (***) were defined as statistically
significant. The Bonferroni procedure was applied for the
correction of multiple testing. The statistical analysis
was performed with the statistical program XLStat2010
(AddinSoft, Paris, France). GraphPad Prism® Version
5.04 for Windows (GraphPad Software Inc., La Jolla,
CA, USA) was used for creating graphics.
Results
This retrospective investigation analyzed the role of the
cytokines IL1-β, sIL-2R, IL-6, IL-8, IL-10 and TNF-α as
potential markers for major post-transplant adverse
events including VOD, skin and intestinal GvHD, sepsis
as well as bacterial, viral and fungal infections in 61
pediatric patients.
The median observation period was 74 days (range
28–245 days) and included the time of measurement
directly before the start of conditioning until the day of
clinical discharge.
Patient group without complications
The group without complications included in this analysis
consisted of 13 of the 61 pediatric patients with a median
age of 7 years (range 11 months to 18 years). 4 (30.8 %) of
the 13 patients had leukemia, 3 (23.1 %) had a solid tumor,
2 (15.4 %) had an immunologic disease, 2 (15.4 %) had an
autoimmune disease, 1 (7.7 %) had a neurometabolic dis-
ease and 1 (7.7 %) had Chédiak-Higashi-syndrome
(Table 1). These patients experienced none of the evalu-
ated adverse events like VOD, acute GvHD, invasive or
localized fungal, viral or bacterial infection during the
conditioning and the observed post-transplant period.
Levels of the cytokines IL-1ß, sIL-2R, IL-6, IL-8, IL-10
and TNF-α, were measured in this cohort twice a week.
During the conditioning and post-transplant period, the
median level of TNF- α (median 5.8 pg/ml, range 4.0 –
10.0 pg/ml) was elevated (>8 pg/ml) in only 4 of 13
patients. The levels of IL-1ß (median 0.1 pg/ml, range
0.1 – 0.4 pg/ml), sIL-2R (median 585 U/ml, range 296–
869 U/ml), IL-6 (median 2.0 pg/ml, range 2.0 – 5.0 pg/
ml), IL-8 (median 14.0 pg/ml, range 5.0 – 56 pg/ml), and
IL-10 (median 3.1 pg/ml, range 1.0 – 6.9 pg/ml) were
within the normal range during the observation period.
Cytokines and stem cell transplantation
The analysis of the cytokine level in the different types
of stem cell transplantation and conditioning regimen
occurred at median on day +2 (range +1 to +4) after
HSCT. The comparison of patients with versus without
TBI did not reveal anystatistically significant difference
in any of the cytokines analyzed (IL-1β: P = 1.0; sIL-2R:
P = 0.228, IL-6: P = 0.912; IL-8: P = 0.645; IL-10: P =
0.868; TNF-α: P = 0.433). As well, comparison of cyto-
kine levels between MUD and MMFD showed no sig-
nificant difference (IL-1β: P = 0.123; sIL-2R: P = 0.588,
IL-6: P = 0.494; IL-8: P = 0.695; IL-10: P = 0.793; TNF-
α: P = 0.426). In contrast to this, the comparison of
MUD and MFD showed significant differences for cyto-
kines IL-1β (mean 0.134 ± 0.058 pg/ml versus 0.624 ±
0.184 pg/ml, respectively; P = 0.0019), sIL-2R (mean 1431
± 1076 U/ml versus 550 ± 165 U/ml, respectively; P =
0.0185) and IL-8 (mean 46.3 ± 37.6 pg/ml versus 16.0 ±
11.7 pg/ml, respectively; P = 0.023). Levels of IL-6 (P =
0.067), IL-10 (P = 0.221) and TNF-α were not signifi-
cantly different in these two groups.
Transplant-related adverse events
Veno-occlusive disease
In 5 (8.2 %) of 61 patients, VOD was diagnosed according
to the clinical and laboratory criteria. The first clinical
symptoms and noticeable changes in laboratory parame-
ters of VOD occurred in these patients at a median on day
18 (range day 13 – 28) after HSCT. All 5 patients had
significantly increased serum levels of IL-6 (P = 0.0313),
IL-8 (P = 0.0156) and TNF-α (P = 0.0313) compared to the
baseline before start of conditioning (Table 2). This
occurred at the same time or shortly before (median
2 days, range 1–3 days) clinical symptoms were diagnosed
(Table 2). None of the 5 pediatric patients with VOD had
a GvHD grade III or IV or a sepsis simultaneously.
Acute GvHD
An acute GvHD appeared in 24 (39.3 %) out of 61
patients. 11 (45.8 %) of these 24 patients experienced a
grade I, 9 (37.5 %) a grade II, 3 (12.5 %) a grade III and 1
(4.2 %) a grade IV GvHD (Table 1). 9 (37.5 %) patients de-
veloped an isolated acute organ GvHD; 6 (25 %) occurred
in the skin, 2 (8.3 %) were isolated intestinal GvHD and
one (4.2 %) occurred as an isolated liver GvHD. Liver
GvHD: Two of the pediatric patients experienced liver
GvHD stage III and stage IV, respectively. In both cases, a
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clear increase in the levels of IL-6, IL-8, IL-10, sIL-2R and
TNF-α could be observed. In one patient, these increases
occurred two days before laboratory chemical changes were
seen for direct and indirect bilirubin and the transaminases
ALT and AST. In the other patient, the cytokine levels and
the laboratory chemical markers changed simultaneously.
However, due to the small number of cases, it was not pos-
sible to detect any statistical significance (Table 2). Intes-
tinal GvHD: In 9 (14.8 %) of the 61 patients an acute
intestinal GvHD was observed. Acute intestinal GvHD
stage I occurred in 2 (22.2 %) patients, while intestinal
GvHD stage II was seen in 6 (66.7 %) . One patient (11.1 %)
suffered from intestinal GvHD stage III. At the onset of the
first clinical symptoms of acute intestinal GvHD with an in-
crease of feces quantity, significant increases of IL-6 (p =
0.0010), IL-10 (p = 0.0039), sIL-2R (p = 0.0020), and TNF-α
(P = 0.0020) were observed in all pediatric patients with
acute intestinal GvHD stage II and III. In both patients with
intestinal GvHD stage I, there was only an increase in cyto-
kine levels of sIL-2R and IL-10. The cytokine levels of IL-8
and IL-1ß did not significantly change in the 9 patients with
intestinal GvHD stage I to III (Table 2). Skin GvHD: A total
of 15 (24.59 %) of the 61 pediatric patients experienced an
acute GvHD of the skin. 6 (40 %) out of 15 patients had a
skin GvHD stage I. 8 (53.3 %) patients suffered from skin
GvHD stage II, while 1 (6.67 %) patient experienced acute
skin GvHD stage III. The 9 patients with a skin GvHD
stage II and III, developed significant increases of IL-6 (P =
0.0010), sIL-2R (P = 0.0049) and TNF-α (P = 0.0020) in the
serum, whereas IL-8, IL-10 and IL-1ß did not significantly
change. 8 of the 9 patients with skin GvHD stage II and III
had an increase in IL-6 a few days before (median 2 days)
the appearance of exanthema of the skin. Cytokines sIL-2R
and TNF-α increased in all 9 pediatric patients with the ap-
pearance of exanthema. The patients with skin GvHD stage
I had either no changes in cytokine levels or only an in-
crease of IL-6 (Table 2).
Sepsis and bacterial infections
11 (18.0 %) of the 61 patients developed sepsis. 5 (8.2 %)
patients had a bacteremia with positive blood cultures. In
Table 2 Cytokine levels at baseline before and at the beginning of the first clinical symptoms of veno-occlusive-disease and organ
specific graft-versus-host disease
Post-transplant-adverse event Serum level Before post-transplant adverse event Post-transplant adverse event
Median Range Median Range P-value
VOD IL-6 pg/ml 3.150 2.0 – 28.0 69.850 7.7 – 197.0 0.0313
IL-8 pg/ml 18.4 5.0 – 54.2 105 13.6 – 200.0 0.0156
IL-10 pg/ml 3.55 2.4 – 4.7 6.20 4.3 – 20.4 n.d.
sIL-2R U/ml 1519.0 397 – 3796 3218.0 1934 – 4666 0.3750
IL-1 ß ng/ml 0.260 0.15 – 0.39 0.335 0.1 – 0.47 0.7500
TNF-α pg/ml 8.00 7.5 – 21.8 22.30 10.5 – 103 0.0313
Acute liver GvHD IL-6 pg/ml 2.0 2.0 – 2.0 28.1 27.5 – 28.7 n.d.
IL-8 pg/ml 20 5.0 – 35.0 526.5 460.0 – 593.0 n.d.
IL-10 pg/ml 2.00 2.0 – 2.0 135.90 98.8 – 173.0 n.d.
sIL-2R U/ml 823 823 – 823 5705.0 2483 – 8927 n.d.
TNF-α pg/ml 4.00 4.0 – 4.0 50.35 32.2 – 68.5 n.d.
Acute intestinal GvHD II-IV IL-6 pg/ml 3.3 2.0 – 26.0 24.3 2.0 – 254.0 0.0010
IL-8 pg/ml 26.65 5.0 – 5702 33.6 10.7 – 460.0 0.2036
IL-10 pg/ml 3.20 2.0 – 7.9 46.25 12.4 – 173 0.0039
sIL-2R U/ml 823.5 397 – 2393 2321.0 1296 – 3586 0.0020
IL-1 ß ng/ml 0.21 0.22 – 0.41 0.21 0.17 – 0.31 0.5000
TNF-α pg/ml 7.20 5.2 – 19.90 28.05 12.4 – 90.6 0.0020
Acute skin GvHD II-IV IL-6 pg/ml 2.15 2.0 – 7.4 8.3 2.5 – 83.2 0.0010
IL-8 pg/ml 10.4 5.0 – 40.0 11.9 5.0 – 47.9 0.2783
IL-10 pg/ml 4.90 2.0 – 7.7 6.60 1.9 – 278.0 0.9453
sIL-2R U/ml 930.5 397 – 2831 1846.0 918 – 8540 0.0049
IL-1 ß ng/ml 0.18 0.1 – 0.39 0.34 0.23 – 0.36 0.5000
TNF-α pg/ml 7.20 4.0 – 17.0 18.20 11.2 – 35.7 0.0020
*P-value: statistical comparison between baseline measurements and during post-transplant adverse events by the Wilcoxon matched pairs signed rank test; n.d.
= not determined due to small sample size
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21 (34.4 %) out of 61 patients 25 localized bacterial
infections were detected over the course of the observation
period. Bacterial infections appeared in the urine (n = 11),
feces (n = 8), throat (n = 5) and bronchoalveolar lavage (n =
1). In the case of sepsis a significant increase of IL-6 (P =
0.0020), IL-8 (P = 0.0020), sIL-2R (P = 0.0156), and TNF-α
(P = 0.0078) was observed in all pediatric patients (n = 8)
for which an analysis of the cytokine levels was performed
on the day of the occurrence of sepsis. These patients also
had a body temperature ≥38.3 °C at that point in time. In
the remaining 3 patients that experienced a sepsis, the final
analysis of cytokine levels was done more than 24 h prior.
Fever was not present at the time blood was taken. There
was no change in the analyzed cytokine levels at this time.
In all 5 (10.42 %) of the 61 patients diagnosed with
bacteremia, a significant increase of IL-6 (P < 0.0001) and
IL-8 (P = 0.0006) was observed (Table 3).
Viral infections
8 (13.2 %) of 61 patients had a viremia (Table 3). CMV
invasive infection was observed in the blood of 6 patients
and an ADV infection was found in the blood of 5
patients. Consequently, both infections occurred in 3
patients. These patients had CMV and ADV infection in
the post-transplant period. In all 11 invasive viral infec-
tions there was a significant increase of IL-6 (P = 0.0008).
These increases occurred at median 3 days (range 1–4
days) prior to positive PCR testing (Table 3).
Fungal infections
6 (9.84 %) of the 61 patients experienced fungemia. In one
case, a probable invasive fungal infection came about, while
5 cases showed a possible invasive fungal infection. In all 6
cases, there were positive signs of Aspergillus galactoman-
nan antigen in the blood in at least two consecutive sam-
ples. No proven invasive fungal infections were observed.
No specific cytokine pattern and no significant alterations
of IL-1ß, sIL-2R, IL-6, IL-8, IL-10 and TNF-α could be ob-
served in any of these cases (Table 3).
Clinically relevant comparisons between infectious post-
transplant adverse events
In order to better distinguish between the different types
of infections, a statistical comparison of cytokine levels
was made during infectious post-transplant adverse
events that are often clinically difficult to distinguish
from each other. A comparison of the occurrence of
Table 3 Cytokine levels at baseline before and at the beginning of the first clinical symptoms of post-transplant related infections
Post-transplant-adverse event Serum level Before post-transplant adverse event Post-transplant adverse event
Median Range Median Range P-value
Sepsis IL-6 pg/ml 11.90 2.0 – 73.6 133.00 23.6 – 2856 0.0020
IL-8 pg/ml 40.0 9.0 – 212.0 650.0 73.4 – 10,385 0.0020
IL-10 pg/ml 7.20 3.6 – 55.9 16.70 14.3 – 98.8 0.0625
sIL-2R U/ml 1780.0 973 – 5933 4899.0 1387 – 9680 0.0156
IL-1 ß ng/ml 0.14 0.1 – 1.99 1.51 0.17 – 3.54 0.0625
TNF-α pg/ml 5.6 4.0 – 25.7 26.9 6.0 – 204.0 0.0078
Bacteremia IL-6 pg/ml 3.7 2 – 205 13.8 2.5 – 267 <0.0001
IL-8 pg/ml 21.1 7.5 – 220 35.2 7.70 – 954 0.0006
IL-10 pg/ml 4.0 1.1 – 26.2 5.5 1.0 – 62.3 0.059
sIL-2R U/ml 1306.0 296 – 6690 1423 414 – 6689 0.2023
IL-1 ß ng/ml 0.1 0.1 – 0.35 0.20 0.10 – 1.08 0.0026
TNF-α pg/ml 8.9 4.0 – 26.4 10.8 4.0 – 456 0.0007
Viremia IL-6 pg/ml 9.2 2.0 – 83.2 11.30 2.0 – 113 0.0008
IL-8 pg/ml 16.00 6.7 – 67.10 18.40 5.0 – 295 0.1867
IL-10 pg/ml 4.10 1.0 – 35.9 4.5 1.0 – 134 0.3884
sIL-2R U/ml 1561.0 461 – 4666 1409 322 – 7284.0 0.7676
IL-1 ß ng/ml 0.1 0.1 – 0.87 0.2 0.1 – 1.48 0.1755
TNF-α pg/ml 11.9 4.0 – 127.0 12.2 4.0 – 137.0 0.2909
Fungemia IL-6 pg/ml 5.00 2.0 – 16.0 7.75 2.0 – 267.0 0.1272
IL-8 pg/ml 23.2 5.0 – 99.9 22.35 5.0 – 243.0 0.5688
IL-10 pg/ml 3.35 1.6 – 5.1 4.90 2.3 – 39.6 0.4375
sIL-2R U/ml 1180.0 397 – 2365 1037.0 322 – 3195 0.1289
IL-1 ß ng/ml 0.1 0.1 – 0.43 0.15 0.1 – 1.01 0.5312
TNF-α pg/ml 10.9 4.0 – 89.1 9.5 4.0 – 61.1 0.2891
P-value: statistical comparison between baseline measurements and during post-transplant adverse events by the Wilcoxon matched pairs signed rank test
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sepsis, bacteremia, viremia and fungemia was done with
all of the examined cytokines.
IL-1β
The comparison of IL-1β values for sepsis (1.7 ± 1.21 pg/
ml) and bacteremia (0.3 ± 0.27 pg/ml; P = 0.125), sepsis
and viremia (0.4 ± 0.39 pg/ml; P = 0.062), sepsis and funge-
mia (0.3 ± 0.29 pg/ml; P = 0.125), bacteremia and viremia
(P = 0.843), bacteremia and fungemia (P = 0.625), and
viremia and fungemia (P = 0.875) showed no significance
after Bonferroni correction (adjusted α = 0.0083) (Fig. 1).
sIL-2R
sIL-2R serum levels during sepsis (5509 ± 2908 U/ml)
and bacteremia (1803 ± 1416 U/ml; P = 0.250), sepsis and
viremia (1783 ± 1374 U/ml; P = 0.375), bacteremia and
viremia (P = 0.983), bacteremia and fungemia (1224 ±
805 U/ml; P = 0.431), and viremia and fungemia (P =
0.695) were not significantly different. There was a
significant difference (P = 0.031) between sepsis (5509 ±
2908 U/ml) and fungemia (1224 ± 805 U/ml). However,
this was insignificant after Bonferroni correction (ad-
justed α = 0.0083) (Fig. 2).
IL-6
A significant decrease (P = 0.002) of IL-6 was found
between sepsis (650 ± 989 pg/ml) and bacteremia (39.63 ±
58.58 pg/ml), as well as between sepsis and viremia
(17.47 ± 22.40 pg/ml; P = 0.002). There was also a signifi-
cant difference (P = 0.001) between sepsis and fungemia
(24.07 ± 58.85 pg/ml). After Bonferroni correction (ad-
justed α = 0.0083) the decrease of IL-6 between bacteremia
and viremia (P = 0.0094) and between bacteremia and fun-
gemia, (P = 0.0194) was not significant. The comparison of
serum IL-6 concentration between viremia and fungemia
(P = 0.305) was neither significant (Fig. 3).
IL-8
There was a significant decrease (P = 0.002) of IL-8 between
sepsis (2406 ± 3190 pg/ml) and bacteremia (93.53 ±
168.8 pg/ml), as well as between sepsis and viremia (32.31 ±
46.23 pg/ml; P = 0.002), and between bacteremia and
viremia (P = 0.0064). There was a decrease (P = 0.0341)
between sepsis and fungemia (47.26 ± 56.93 pg/ml). This
was, however, insignificant after Bonferroni correction.
Fig. 1 IL-1β concentrations during post-transplant infectious
complications. Data show mean IL-1β serum concentrations in
occurrence of sepsis (1.7 ± 1.21 pg/ml), bacteremia (0.3 ± 0.27 pg/ml),
viremia (0.4 ± 0.39 pg/ml) and fungemia (0.3 ± 0.29 pg/ml). Data
show mean +95 % confidence interval (CI)
Fig. 2 sIL-2R concentrations during post-transplant infectious complications.
Data show mean sIL-2R serum concentrations in occurrence of sepsis
(5509 ± 2908 U/ml), bacteremia (1803 ± 1416 U/ml), viremia (1783 ± 1374
U/ml) and fungemia (1224 ± 805 U/ml). Data show mean +95 % CI
Fig. 3 IL-6 concentrations during post-transplant infectious
complications. Data show mean IL-6 serum concentrations in
occurrence of sepsis (650 ± 989 pg/ml), bacteremia (39.63 ±
58.58 pg/ml), viremia (17.47 ± 22.40 pg/ml) and fungemia (24.07 ±
58.85 pg/ml). Data show mean +95 % CI; **: P < 0.01; ***: P < 0.001
Döring et al. BMC Cancer  (2015) 15:607 Page 7 of 11
The comparison of IL-8 serum concentration between
viremia and fungemia (P = 0.161) and between bacteremia
and fungemia (P = 0.15), showed no significant changes.
Due to the large scattering of the measured values and
high maximum values, the standard deviations are often
much larger than the mean values (Fig. 4).
IL-10
A significant decrease (P = 0.005) of IL-10 serum con-
centration was found between sepsis (32.82 ± 36.91 pg/
ml) and viremia (12.60 ± 26.47 pg/ml). All other pairwise
comparisons were statistically insignificant. IL-10 serum
concentrations in occurrence of sepsis showed no sig-
nificant changes in comparison to bacteremia (28.12 ±
15.96 pg/ml). The comparison of sepsis with the funge-
mia (10.59 ± 13.39 pg/ml), also showed no significant
change. When comparing viremia and fungemia (P =
0.50), bacteremia and fungemia (P = 0.50) and
bacteremia and viremia (P = 0.31), no significant changes
in IL-10 serum concentration were found after Bonfer-
roni correction (adjusted α = 0.0083) (Fig. 5).
TNF-α
After Bonferroni correction, there was no significant de-
crease (P = 0.046) of TNF-α between sepsis (55.42 ±
63.04 pg/ml) and fungemia (13.37 ± 12.60 pg/ml). Sepsis
compared to bacteremia (25.95 ± 68.32; P = 0.85) and to
viremia (18.88 ± 22.64; P = 0.322) showed no significant
changes in TNF-α serum concentrations. Moreover, the
comparison of TNF-α concentrations in occurrence of
bacteremia in relation to both fungemia (P = 0.614) and
viremia (P = 0.884) was not significant. A comparison of
the TNF-α concentration between viremia and fungemia
also showed no significance (P = 0.091) after Bonferroni
correction (adjusted α = 0.0083) (Fig. 6).
Discussion
The primary objective of this retrospective investigation
was to analyze whether early identification of major post-
transplant adverse events in pediatric patients with
hemato-oncological malignancies and non-malignancies
after HSCT is possible through the examination of cyto-
kine levels. Early identification of these post-transplant
Fig. 4 IL-8 concentrations during post-transplant infectious
complications. Data show mean IL-8 serum concentrations in
occurrence of sepsis (2406 ± 3190 pg/ml), bacteremia (93.53 ±
168.80 pg/ml), viremia (32.31 ± 46.23 pg/ml) and fungemia
(47.26 ± 56.93 pg/ml). Data show mean +95 % CI; **: P < 0.01
Fig. 5 IL-10 concentrations during post-transplant infectious
complications. Data show mean IL-10 serum concentrations in
occurrence of sepsis (32.82 ± 36.91 pg/ml), bacteremia (12.28 ±
15.96 pg/ml), viremia (12.60 ± 26.47 pg/ml) and fungemia (10.59 ±
13.39 pg/ml). Data show mean +95 % CI; **: P < 0.01
Fig. 6 TNF-α concentrations during post-transplant infectious
complications. Data show mean TNF-α serum concentration in
occurrence of sepsis (55.42 ± 63.04 pg/ml), bacteremia (25.95 ±
68.32 pg/ml), viremia (18.88 ± 22.64 pg/ml) and fungemia (13.37 ±
12.60 pg/ml). Data show mean +95 % CI
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adverse events is required for timely and adequate treat-
ment and thus has decisive impact on patient outcome.
This analysis focused on finding markers that could
help to differentiate post-transplant complications with
similar initial clinical symptoms and laboratory parame-
ters. These include for example, distinguishing a VOD
from liver GvHD, a localized viral infection in feces from
an intestinal GvHD, and the various types of invasive
infections like bacteremia, viremia, and fungemia. In
order to do this, we carried out a single center survey
that analyzed the cytokine levels of IL-1ß, sIL-2R, IL-6,
IL-8, IL-10, sIL-2R and TNF-α during conditioning, and
during the post-transplant period in 61 pediatric patients
and young adults after allogeneic and autologous HSCT.
Occurrences of the first laboratory chemical changes or
clinical symptoms of a VOD coincided with a significant
increase in cytokine levels of IL-6, IL-8 and TNF-α. This
observation is in line with the results of a study in which
the levels of TNF-α, IL-6, and IL-8 were analyzed in 53
patients undergoing HSCT. Elevation of these cytokines
in association with hepatic dysfunction (defined as
increased bilirubin levels) also occurred in VOD patients
[34]. In another analysis of adult transplanted patients
high IL-8 levels were detected during severe VOD in 6
patients, 5 of whom showed elevated levels of IL-6 [13].
Furthermore, a study of 10 patients with VOD found a
significant increase in the levels of sIL-2R (P < 0.001)
with mean values of 4546 ± 1420 U/ml in contrast with a
control group without major complications after HSCT
[14]. When this is compared to the values observed in the
present trial, which displayed a median of 3218 U/ml,
similarly significant values can be observed (P = 0.0011)
when compared to the levels detected in the healthy con-
trol group (median 585 U/ml, range 296.0–869.0 U/ml).
In cases of liver GvHD, there was a further increase in
sIL-2R and IL-10 along with the increase in levels of cyto-
kine IL-6, IL-8, and TNF-α. These two markers, sIL-2R
and IL-10, may be used to differentiate a VOD from a liver
GvHD.
In cases of an intestinal GvHD, the same cytokine pat-
tern was shown as in acute skin GvHD, with a signifi-
cant increase in sIL-2R, IL-6 and TNF-α. The only
differentiator of intestinal GvHD was the additional
significant increase of IL-10 in comparison to the skin
GvHD, which showed no changes in IL-10 levels. Several
studies have shown that elevated TNF-α levels after
HSCT are associated with the presence of acute GvHD
and that the TNF-α levels increase nearly simultaneously
with the onset of acute GvHD [17, 20, 35]. The limited
published data on cytokine levels of relevant viral infec-
tions in immunosuppressed patients show similar re-
sults. In an analysis of 14 patients with a reactivation of
HHV-6, IL-6 levels were significantly higher than in
patients without HHV-6 activation [9].
However, in the present analysis it was difficult to
differentiate a viremia from a bacteremia by examining
cytokine levels. In both bacteremia and viremia, an
isolated significant increase of IL-6 was observed. In
another retrospective study, significant increases of
IL-6, IL-8 and sIL-2R were observed during the analysis
of febrile episodes before bacteremia caused by gram-
negative bacteria [36]. In pediatric patients with sepsis,
a cytokine storm occurred with an increase of sIL-2R,
IL-6, IL-8, and TNF-α [37]. The observations of the
present investigation are also consistent with another
analysis of 79 pediatric patients with sepsis. These pa-
tients displayed significantly higher TNF-α levels than
patients with negative blood cultures [38].
In the present analysis, the cytokines IL-6, IL-8 and
IL-10 played a central role when differentiating between
the different types of infectious post-transplant compli-
cations. It could be found that the cytokine IL-6 can sig-
nificantly distinguish between sepsis and fungemia (P =
0.0010), sepsis and viremia (P = 0.0020), and sepsis and
bacteremia (P = 0.0020). However, a differentiation be-
tween bacteremia and viremia, bacteremia and fungemia,
and viremia and fungemia was not significant. Further-
more, the cytokine IL-8 enabled significant differenti-
ation (P = 0.0020) between sepsis and viremia and sepsis
and bacteremia. A distinction between sepsis and funge-
mia was not possible. In addition, IL-8 facilitates a
significant distinction between bacteremia and viremia
(P = 0.0064), and IL-10 can differentiate between sepsis
and viremia (P = 0.005).
Conclusions
The presented retrospective survey shows that the ana-
lysis of cytokines enables differentiation of major post-
transplant complications. A significant increase in cyto-
kine levels of IL-6, IL-8, and TNF-α announces the
beginning of a VOD. For suspected cases of intestinal
GvHD ≥ grade II, a significant increase of cytokines IL-6,
IL-10, sIL-2R and TNF-α may serve as an early identifi-
cation marker. A significant increase of IL-6 alone was
associated with ADV-viremia and significant increases of
IL-6 and IL-8 with bacteremia. Separate from this, a
sepsis was characterized by significant increases of IL-6,
IL-8 and sIL-2R. Analysis of the cytokines allowed differ-
entiation of post-transplant adverse events with similar
clinical symptoms (for example intestinal GvHD and
diarrhea due to viral infection, or VOD and liver GvHD).
However, studies with larger patient cohorts and a pro-
spective setting will be performed to validate these
conclusions in order to use characteristic cytokine
patterns to identify post-transplant adverse events as
early as the onset of fever with unknown origin or other
initial clinical symptoms, and thus facilitate a correct
treatment approach.
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